

RESEARCH

Open Access



# Ciliated muconodular papillary tumors of the lung with *KRAS/BRAF/AKT1* mutation

Emiko Udo<sup>1</sup>, Bungo Furusato<sup>1\*</sup>, Kazuko Sakai<sup>2</sup>, Leah M Prentice<sup>3</sup>, Tomonori Tanaka<sup>2</sup>, Yuka Kitamura<sup>1</sup>, Tomoshi Tsuchiya<sup>4</sup>, Naoya Yamasaki<sup>4</sup>, Takeshi Nagayasu<sup>4</sup>, Kazuto Nishio<sup>2</sup> and Junya Fukuoka<sup>1</sup>

## Abstract

**Background:** Ciliated muconodular papillary tumors (CMPTs) are newly recognized rare peripheral lung nodules that are histologically characterized by ciliated columnar, goblet, and basal cells. Although recent studies have shown that CMPTs constitute a neoplastic disease, the complete histogenesis of CMPTs is not fully understood and molecular data are limited.

**Methods:** We reviewed four cases of CMPT and performed immunohistochemical and genomic analyses to establish CMPT profiles.

**Results:** All cases were positive for hepatocyte nuclear factor-4a and mucin 5B and negative for programmed death ligand 1 expression, as determined by immunohistochemistry. The genetic analysis revealed three pathogenic mutations (*BRAF* V600E, *AKT1* E17K, and *KRAS* G12D), with the *KRAS* mutation reported here for the first time.

**Conclusion:** Histological and genetic profiles indicate that CMPTs are likely neoplastic and exhibit features similar to mucinous adenocarcinoma. This suggests that some CMPTs may be a precursor lesion of mucinous adenocarcinoma.

**Keywords:** Ciliated muconodular papillary tumor, CMPT, Next-generation sequencing, Mutation, *BRAF*, *RAS*, *AKT1*

## Background

Ciliated muconodular papillary tumors (CMPTs) are a newly recognized small-size papillary tumor of the peripheral lung that contain columnar cells, occasional basal cells, and mucus-producing cells as well as extracellular mucin pools of various sizes. Although CMPTs were first described based on certain pathological features that suggested a malignant potential, similar diseases such as extremely well-differentiated papillary adenocarcinoma with prominent cilia formation have been reported under different names [1–3]. Due to its complex histology and presence of inflammation and fibrosis, the metaplastic nature of CMPTs has been debated. However, recent reports have revealed the frequent presence of driver gene mutations, and CMPT is now recognized as a neoplasia [4–6]. The histogenesis

and molecular characteristics of CMPTs are not well understood owing to the rarity of the disease. To address this issue, we reviewed our case archive and characterized CMPTs by immunohistochemistry and next-generation sequencing (NGS).

## Methods

### Patient selection and tissue preparation

Cases of surgically resected CMPT from 2012 and 2016 were searched in the pathology archive of Nagasaki University Hospital. Hematoxylin and eosin-stained slides of each case were reviewed by two pathologists specializing in thoracic medicine. We identified four CMPT cases; two of these had been originally diagnosed as CMPT, whereas the other cases had been diagnosed as glandular papilloma and mucinous adenocarcinoma. Clinical data were extracted from the hospital's electronic medical records. Sections with a thickness of 4 μm from formalin-fixed, paraffin-embedded (FFPE) tissue samples were examined by immunohistochemistry, and 15 sections with

\* Correspondence: [bfurusato@nagasaki-u.ac.jp](mailto:bfurusato@nagasaki-u.ac.jp)

<sup>1</sup>Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan  
Full list of author information is available at the end of the article

a thickness of 5  $\mu\text{m}$  were subjected to NGS of 50 cancer-related genes using the Ion Torrent PGM system (Life Technologies, Carlsbad, CA), and 10  $\mu\text{m}$  thick section on the conventional glass slide were submitted for 29 genes analysis using MiSeq (Illumina, San Diego, CA, USA).

#### Isolation of genomic DNA

Genomic DNA was extracted from FFPE tumor samples using the QIAamp DNA FFPE kit (Qiagen, Valencia, CA, USA), and the concentration was determined using the Quant-iT PicoGreen dsDNA Assay kit (Life Technologies).

#### Targeted deep sequencing of mutational hotspots in 50 cancer-related genes

Genomic DNA was subjected to whole-exome sequencing using the Ion AmpliSeq Cancer Hotspot Panel v.2 (Life Technologies) according to the manufacturer's instructions. The purified library was sequenced on an Ion PGM instrument using Ion PGM Hi-Q Sequencing kit and Ion 318 Chip Kit v.2 (all from Life Technologies). DNA sequencing data were accessed with the Torrent Suite v.5.0 program (Life Technologies). The coverage analysis was performed using the coverage analysis plugin v5.0. Reads were aligned with the hg19 human reference genome, and potential mutations were identified using Variant Call Format v.5.0. Raw variant calls were annotated with CLC Genomics Workbench software (CLC bio, Aarhus, Denmark). Variants were manually verified using the integrative genomics viewer (Broad Institute, Cambridge, MA, USA). Known single nucleotide polymorphisms were identified using the Human Genetic Variation Database (<http://www.hgvd.genome.med.kyoto-u.ac.jp/>) [7] and were excluded.

We also performed sequencing on Illumina MiSeq instrument. As recommended by the manufacturer, 50 ng of dsDNA was used for generating sequencing libraries using Find-It cancer hotspot panel (Contextual Genomics, Vancouver, BC, Canada). The panel targets 90+ cancer hotspot mutations including eight coding exons in 29 cancer-related genes. DNA libraries were denatured and diluted as per Illumina's recommendations. Samples were run on MiSeq machine using 300 cycle MiSeq Reagent Kit V2 (Cat.No.MS-102-2002, Illumina).

#### Immunohistochemistry

Immunohistochemical analysis of 4- $\mu\text{m}$  tissue sections was carried out using the Ventana Bench Mark XT Automated stainer (Ventana Medical Systems, Tucson, AZ, USA) and BOND III fully automated stainer (Leica Biosystems, Melbourne, Australia) with antibodies against thyroid transcription factor (TTF)-1 (clone SPT24; Leica Novocastra, Newcastle Upon Tyne, UK), hepatocyte

nuclear factor (HNF)-4 $\alpha$  (clone H1415; Perseus Proteomics, Tokyo, Japan), mucin (MUC)5B (Santa Cruz Biotechnology, Santa Cruz, CA, USA), MUC5A (clone CLH2; Leica Novocastra), cytokeratin (CK)7 (clone OV-TL12/30; Dako Japan, Tokyo, Japan), CK20 (clone Ks20.8; Dako Japan), p53 (clone DO-7; Leica Novocastra), Ki-67 (clone MIB-1; Dako Japan), Caudal-type homeobox (CDX)2 (clone EPR2764Y; Roche Diagnostics, Indianapolis, IN, USA), ALK (clone D5F3; Roche Diagnostics), BRAF V600E (clone VE1; Roche Diagnostics) and programmed death ligand (PD-L)1 (clone SP142; Spring Bioscience, Pleasanton, CA, USA). Details of optimized staining protocols are listed in Additional file 1. HNF4 $\alpha$ , MUC5B, MUC5A, CK7, and CK20 staining was scored as follows: -, negative; 1+, focal; and 2+, diffuse. The intensity of p53 expression was assessed as follows: 1+, faint and sporadic; 2+, frequently positive with no or equivocal overexpression; and 3+, unequivocal and diffuse overexpression. BRAF V600E and ALK expression was judged as positive when strong and diffuse staining was observed in cancer cells. The percentage of Ki-67-immunopositive cells was analyzed using a nuclear algorithm (Nuclear\_v.9\_v.10.0.0.1798; ImageScope, Leica Biosystems, Nussloch, Germany). PD-L1 expression was scored as the percentage of PD-L1-positive cells among tumor cells. CDX2 expression was scored as follows: -, negative; 1+,  $\leq 25\%$  positive; 2+,  $> 25$  and  $< 50\%$  positive; and 3+,  $\geq 50\%$  positive. Two observers (E.U. and J.F.) independently scored the staining and a consensus was obtained through discussion when there was a discrepancy.

## Results

### Clinical summary

Clinical data for the four CMPT patients are summarized in Table 1. The patients were all female with a median age of 67 years old. None had a history of smoking. Tumors ranged in size from 8 to 25 mm (median: 11 mm). Lobectomy was performed in three cases, and segmentectomy was carried out in one case.


### Histological findings

The histological features of the four CMPT cases were consistent with those previously reported [1, 8, 9]. That is, the tumors typically exhibited a mixture of acinar and papillary growth patterns without clear evidence of invasion, and were surrounded by abundant mucus pools in the alveolar spaces (Fig. 1a). The tumors were composed of two basal cell layers and surface epithelia. The latter consisted of an uneven mosaic of ciliated columnar, goblet, and mucin-producing epithelial cells of the gastric type (Fig. 1b). Few tumor cells showed nuclear atypia, and no mitosis or necrosis was observed.

**Table 1** Summary of clinical data and detected gene mutations in the past reports and present cases

| Author            | Age (median) | Sex (M/F) | smoking habit (Y/N) | Driver Mutation   | Other Mutations   | NGS panel   |
|-------------------|--------------|-----------|---------------------|---|---|---|
| Kamata et al. [4] | 62           | 7/3       | 5/5                 | <i>BRAF</i> V600E, 4 cases; <i>EGFR</i> ex19del E746-T751, 3 cases; <i>BRAF</i> G606R, 1 case | <i>IDH1</i> G123R, 1 case; <i>CTNNB1</i> D32N, 1 case; <i>PTPN11</i> E76K, 1 case; <i>PTPN11</i> P491L, 1 case; <i>TP53</i> L289F, 1 case | Ion AmpliSeq Cancer Hotspot Panel v2  |
| Liu et al. [5]    | –            | 1/3       | –                   | <i>BRAF</i> V600E, 1 case   | <i>AKT1</i> E17K, 1 case  | Ion AmpliSeq Cancer Hotspot Panel v2  |
| Lau et al. [15]   | 19           | 0/1       | 0/1                 | none  | none  | Ion AmpliSeq Colon and lung cancer panel                                    |
| Our series        | 67           | 0/4       | 0/4                 | <i>BRAF</i> V600E 1 case<br><i>KRAS</i> G12D, 1 case  | <i>AKT1</i> E17K, 1 case  | Ion AmpliSeq Cancer Hotspot Panel v2; The Contextual Genomics Find-It™ test |

F female, M male



**Fig. 1** Immunohistochemical analysis of CMPTs. **a** Low magnification view of a CMPT showing papillary epithelial proliferation with abundant mucus production. **b** Higher magnification view of the same case showing a mixture of goblet, ciliated columnar, and basal cells (arrow). **c** HNF-4 $\alpha$  positivity in epithelial cell nuclei. Scale bar = 60  $\mu$ m. **d** The positive rate for Ki-67 expression was <10%. Scale bar = 100  $\mu$ m. **e** Focal MUC5AC staining in occasional ciliated cells. Scale bar = 90  $\mu$ m. **f** Epithelial cells and mucin were strongly positive for MUC5B. Scale bar = 2 mm. **g** *BRAF* V600E staining was strong and diffuse in most epithelial cells of a case harboring *BRAF* V600E and *AKT1* E17K mutations. Scale bar = 60  $\mu$ m. **h** PD-L1 staining was mostly negative (< 1%); however, focal membranous immunoreactivity was observed. Scale bar = 70  $\mu$ m

**Immunohistochemistry**

All four cases were positive for nuclear HNF4α and TTF-1. Two cases showed diffuse and strong staining for HNF4α, as seen in mucinous adenocarcinoma or colorectal carcinoma (Fig. 1c). The Ki-67 index was low (2.5%–10%), consistent with a less aggressive nature (Fig. 1d). In contrast to mucinous adenocarcinoma, all cases examined in this study showed diffuse TTF-1 positivity and one case showed possible overexpression. There was sparse cytoplasmic expression of MUC5AC (Fig. 1e) while diffuse MUC5B—which is very rare in the normal lung parenchyma—was detected in all cases (Fig. 1f). Nuclear expression of p53 was sporadic in one case and more frequent in two cases, and in one case p53 was clearly overexpressed. There were no or only a few cells that were positive for CDX2 and CK20. p63 expression highlighted the basal layers in all cases, although the area of coverage was focal in two cases and broad in the two others (Table 2).

One case with *BRAF* V600E mutation identified by NGS showed diffuse and strong BRAF V600E staining, while the other three cases showed none (Fig. 1g). There was no *ALK* and *EGFR* mutations identified in our cases. *ALK* status was also confirmed by immunohistochemistry.

All cases exhibited <1% PD-L1 positivity in tumor cell membranes (Fig. 1h). These findings suggest that CMPTs are tumors that originated from a terminal respiratory unit and are showed features of gastric-type glands.

**Genetic analysis**

Gene mutations were detected in two of the four cases (50%) (Table 1). One case harbored *BRAF* V600E and *AKT1* E17K mutations—which was interestingly identical as what have been recently reported [4, 5]—and another had a *KRAS* G12D mutation. The detected mutation status was identical on both Ion PGM instrument system and Illumina MiSeq system. A *KRAS* G12C

mutation was found in one of the two other cases; however, the significance of this mutation is unclear due to its low frequency.

**Discussion**

We carried out immunohistochemical and molecular analyses of four cases of CMPT and identified a previously unreported *KRAS* mutation in addition to known *BRAF* and *AKT1* mutations. The findings of *BRAF* and *AKT1* mutations were identical to those reported in recent studies [4, 5]. However, we could not identify either *EGFR* or *ALK* mutation in our cases [4, 6, 10].

Interestingly, the case with a *KRAS* G12D mutation detected by Ion PGM and Illumina method showed fewer basal cell layers, as confirmed by p63 immunostaining, while another case with reduced basal cell layer coverage also had a *KRAS* mutation (G12C). We did not take this mutation into account due to its low frequency by Ion PGM method and negative result by Illumina method. This *KRAS* status could be due to intratumoral heterogeneity—i.e., the few cells harboring this mutation may have been overshadowed by wild-type cells, which constituted the majority of the tumor cells.

Our immunostaining results were consistent with previous reports [6, 8, 10–16]. However, we showed for the first time that CMPTs were positive for HNF-4α and MUC5B. Although these tumors show similarities to mucinous adenocarcinoma, there are significant differences between them such as the presence of cilia in columnar epithelia and basal cell intervention in the latter. In addition, invasive mucinous adenocarcinoma is usually TTF-1-negative and has distinct malignant features [17].

**Conclusion**

This is the first report of CMPTs of the lung harboring a *KRAS* mutation. Our findings suggest that CMPT cases

**Table 2** Summary of immunohistochemical findings in previous reports and present cases

| Author                | TTF-1          | Ki67          | CK7 | CK20 | MUC5AC                            | MUC5B | p53 | HNF4α             | p63/p40          | CDX2 | PD-L1   | ALK | <i>BRAF</i> V600E |
|-----------------------|----------------|---------------|-----|------|-----------------------------------|-------|-----|-------------------|------------------|------|---------|-----|-------------------|
| Sato et al. [8]       | 2/2            | 3%; 10%       | 2/2 | 0/2  | 1/2                               | -     | -   | -                 | -                | -    | -       | -   | -                 |
| Chuang et al. [14]    | 1/1            | <1%           | 1/1 | 0/1  | -                                 | -     | 0/1 | -                 | 1/1              | -    | -       | -   | -                 |
| Chu et al. [13]       | 1/1            | -             | 1/1 | 0/1  | -                                 | -     | -   | -                 | 1/1              | -    | -       | -   | -                 |
| Kon et al. [12]       | 5/5            | <1%; 5        | 5/5 | 0/5  | 0/5                               | -     | 0/5 | -                 | 5/5              | -    | -       | -   | -                 |
| Lau et al. [15]       | 1/1            | not increase  | 1/1 | 0/1  | 1/1(weak)                         | -     | -   | -                 | 1/1              | -    | -       | -   | -                 |
| Kamata et al. [4, 11] | + <sup>a</sup> | -             | -   | -    | + <sup>a</sup><br>(cliated cells) | -     | -   | 0/10 <sup>a</sup> | + <sup>a</sup>   | -    | -       | -   | 4/4 <sup>b</sup>  |
| Ishikawa et al. [16]  | 3/5            | <5% 3; <10% 1 | 5/5 | 0/5  | -                                 | -     | 3/3 | -                 | -                | -    | -       | -   | -                 |
| Taguchi et al. [10]   | 0/1            | 3.7%          | 1/1 | 0/1  | 1/1                               | -     | <1% | -                 | 1/1              | -    | -       | 1/1 | 0/1               |
| Jin et al. [6]        | 1/1            | -             | 1/1 | -    | -                                 | -     | -   | -                 | 1/1              | -    | -       | 1/1 | -                 |
| Our series            | 4/4            | <5% 3; <10% 1 | 4/4 | 0/4  | 4/4                               | 4/4   | 1/4 | 4/4               | 4/4 <sup>d</sup> | 0/4  | <1% 4/4 | 0/4 | 1/4 <sup>c</sup>  |

-; not available, <sup>a</sup>numbers of positive/negative not reported, <sup>b</sup>cases with BRAF mutation, <sup>c</sup>case with BRAF mutation was positive (1/1), <sup>d</sup>one case was a few as positive

are heterogeneous, and some CMPT cases may be a pre-cancerous form of invasive mucinous adenocarcinoma, although additional studies are needed to investigate this possibility.

## Additional file

**Additional file 1:** Antibodies used for immunohistochemistry. (XLSX 10 kb)

## Abbreviations

(HNF)-4 $\alpha$ : Hepatocyte nuclear factor 4 $\alpha$ ; ALK: Anaplastic lymphoma kinase; CDX2: Caudal-type homeobox 2; CK: Cytokeratin; CMPT: Ciliated muconodular papillary tumor; EGFR: Epidermal growth factor receptor; FFPE: Formalin-fixed, paraffin-embedded; MUC: Mucin; NGS: Next generation sequencing analysis; PD-L1: Programmed death ligand 1; TTF-1: Thyroid transcription factor-1

## Acknowledgments

The authors are sincerely grateful to Professor Hiroaki Ikeda, Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Professor Kazuto Ashizawa, Unit of Translational Medicine, Department of Clinical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Assistant Professor Hiroyuki Yamaguchi, Second Department of Internal Medicine, Nagasaki University School of Medicine, Professor Mitsuko Masutani, Department of Frontier Life Sciences, Nagasaki University Graduate School of Biochemical Sciences, Associate professor Chizu Fukushima, Clinical Research Center, Nagasaki University Hospital for supporting NGS research by the Nagasaki University Priority Research Subject Project Based on Medium-term Goals and Plans fund.

The authors are sincerely grateful to Masakazu Souda, Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Yuki Imaoka, Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences for their technical assistances.

## Funding

Nagasaki University Priority Research Subject Project Based on Medium-term Goals and Plans.

## Availability of data and materials

All data is available upon request to the corresponding author.

## Authors' contributions

EU conceived of the study design, participated in immunostaining, molecular analysis of NGS and execution of the study. BF received a research grant, conceived of the study design and reviewed manuscript. KS supervised all procedure of NGS and assisted in drafting the manuscript. PL supervised all procedure of NGS and assisted in drafting the manuscript. TT participated in histological analysis. YK participated in providing clinical data and execution of the study. TT participated in providing clinical data. NY participated in providing clinical data. TN participated in providing clinical data. KN participated in molecular analysis, supervised NGS and execution of the study. JF conceived of the study design, and reviewed manuscript. All authors participated for data analysis and approved the final version.

## Ethics approval and consent to participate

All procedures performed in this study were approved by the ethical committee at Nagasaki University (approval no.16052328).

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Author details

<sup>1</sup>Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.

<sup>2</sup>Department of Genome Biology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan. <sup>3</sup>Contextual Genomics, Suite #204 Donald Rix Building 2389 Health Sciences Mall, Vancouver V6T 1Z3, BC, Canada. <sup>4</sup>Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.

Received: 17 May 2017 Accepted: 24 July 2017

Published online: 22 August 2017

## References

- Ishikawa Y. Ciliated muconodular papillary tumor of the peripheral lung: benign or malignant. *Patholo Clin Med (Bryouri-to-Rinsho)*. 2002;20:964–5.
- Nakamura S, Koshikawa T, Sato T, Hayashi K, Suchi T. Extremely well differentiated papillary adenocarcinoma of the lung with prominent cilia formation. *Acta Pathol Jpn*. 1992;42:745–50.
- Harada T, Akiyama Y, Ogasawara H, Kishi F, Hattori A, Okamoto K, Hiramatsu M, Ishikawa Y. Ciliated muconodular papillary tumor of the peripheral lung: a newly defined rare tumor. *Respir Med*. 2008;1:3.
- Kamata T, Sunami K, Yoshida A, Shiraishi K, Furuta K, Shimada Y, Katai H, Watanabe S, Asamura H, Kohno T, Tsuta K. Frequent *BRAF* or *EGFR* mutations in ciliated muconodular papillary tumors of the lung. *J Thorac Oncol*. 2016;11:261–5.
- Liu L, Aesif SW, Kipp BR, Voss JS, Daniel S, Aubry MC, Boland JM. Ciliated muconodular papillary tumors of the lung can occur in Western patients and show mutations in *BRAF* and *AKT1*. *Am J Surg Pathol*. 2016;40:1631–6.
- Jin Y, Shen X, Shen L, Sun Y, Chen H, Li Y. Ciliated muconodular papillary tumor of the lung harboring ALK gene rearrangement: Case report and review of the literature. *Pathol Int*. 2017;67:171–5.
- Kogita A, Yoshioka Y, Sakai K, Togashi Y, Sogabe S, Nakai T, Okuno K, Nishio K. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis. *Biochem Biophys Res Commun*. 2015;458:52–6.
- Sato S, Koike T, Homma K, Yokoyama A. Ciliated muconodular papillary tumour of the lung: a newly defined low-grade malignant tumour. *Interact Cardiovasc Thorac Surg*. 2010;11:685–7.
- Hata Y, Yuasa R, Sato F, Otsuka H, Goto H, Isobe K, Mitsuda A, Wakayama M, Shibuya K, Takagi K, Watanabe Y. Ciliated muconodular papillary tumor of the lung: a newly defined low-grade malignant tumor with CT findings reminiscent of adenocarcinoma. *Jpn J Clin Oncol*. 2013;43:205–7.
- Taguchi R, Higuchi K, Sudo M, Kenji M, Miyamoto T, Mishima O, Kitano M, Azuha K, Ito N. A case of anaplastic lymphoma kinase (ALK)-positive ciliated muconodular papillary tumor (CMPT) of the lung: Case report and review of the literature. *Pathol Int*. 2017;67:99–104.
- Kamata T, Yoshida A, Kosuge T, Watanabe S, Asamura H, Tsuta K. Ciliated muconodular papillary tumors of the lung: a clinicopathologic analysis of 10 cases. *Am J Surg Pathol*. 2015;39:753–60.
- Kon T, Baba Y, Fukai I, Watanabe G, Uchiyama T, Murata T. Ciliated muconodular papillary tumor of the lung: a Report of five cases. *Pathol Int*. 2016;66:633–9.
- Chu HH, Park SY, Cha EJ. Ciliated muconodular papillary tumor of the lung: The risk of false-positive diagnosis in frozen section. *Hum Pathol Case Reports*. 2017;7:8–10.
- Chuang HW, Liao JB, Chang HC, Wang JS, Lin SL, Hsieh PP. Ciliated muconodular papillary tumor of the lung: a newly defined peripheral pulmonary tumor with conspicuous mucin pool mimicking colloid adenocarcinoma: a case report and review of literature. *Pathol Int*. 2014;64:352–7.
- Lau KW, Aubry MC, Tan GS, Lim CH, Takano AM. Ciliated muconodular papillary tumor: a solitary peripheral lung nodule in a teenage girl. *Hum Pathol*. 2016;49:22–6.
- Ishikawa M, Sumitomo S, Imamura N, Nishida T, Mineura K, Ono K. Ciliated muconodular papillary tumor of the lung: report of five cases. *J Surg Case Rep*. 2016;2016:rjw144.
- Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. *Histopathology*. 2000;36:8–16.